



Program

13th International Workshop on Waldenstrom's Macroglobulinemia October 14-16, 2026, Palm Springs, California-USA

Tuesday, October 13, 2026

[2:00-5:00 PM] Early Registration
California Grand Ballroom Foyer

[6:00-8:00 PM] Welcome Reception
Renaissance Oasis Veranda

Wednesday, October 14, 2026 **California Grand Ballroom**

[8:00-9:00 AM] Session I
Genomic Predispositions in WM
Tina Bagratuni, Zachary Hunter [Chairs]

Single Cell Analysis Reveals Multiple Monoclonal Populations in WM and Its Precursor Stages
Minghao Dang, MD Anderson, United States

Multiclonal Disease Underlies Familial WM
Alberto Guijosa, Dana Farber Cancer Institute, United States

Spatial Profiling Reveals Tumor Microenvironmental Alterations in Asymptomatic WM progression
Irene Ghobrial, Dana Farber Cancer Institute, United States

Importance of 6q loss revealed in a MYD88 Transgenic Model of WM
Filip Garbicz, Dana Farber Cancer Institute, United States

Panel Discussion, All Session I Speakers

[9:00-10:00 AM] Session II

Genomic Landscape of the WM Clone

Damien Roos-Weil, Romanos Pistofidis-Sklavenitis [Chairs]

Genomic Evolution of WM Across Disease Stages

Jithma Abeykoon, Mayo Clinic-Rochester, United States

Time-Dependent Genomic Evolution of WM Revealed by the E-Score

Zachary Hunter, Dana Farber Cancer Institute, United States

Subtype Specific Evolutionary Trajectories in WM

Gareth Morgan, New York University-Langone, United States

Secondary Genomic Alterations Associated with MYD88-Driven Oncogenesis

Maria Luisa Guerrero, Dana Farber Cancer Institute, United States

Panel Discussion, All Session II Speakers

**[10:00-10:30 AM] Mid-Morning Break & Networking
Ballroom Terrace**

[10:30-11:30 AM] Session III

High Risk Genomics in WM

Gareth Morgan, Ramon Garcia Sanz [Chairs]

Prognostic Significance of TP53 Mutations from the BLOWM Study

Marzia Varettoni, University of Pavia, Italy

Genomic Landscape of High-Risk WM Disease

David Moreno, University of Barcelona, Spain

High Risk Genomics in the Era of BTK-Inhibitors

Shuhua Yi, Chinese Academy of Medical Sciences, China

Double HIT TP53 Alterations Define Ultra High-Risk WM

Steve Treon, Dana Farber Cancer Institute, United States

Panel Discussion, All Session III Speakers

[11:30-12:30 PM] Session IV

Tumor Immune Microenvironment

Stephen Ansell, Adolfo Aleman [Chairs]

Evolution of Tumor Immune Microenvironment

Romanos Pistofidis-Sklavenitis, City of Hope, United States

Tumor Immune Microenvironmental Interactions in WM

Hao Sun, Dana Farber Cancer Institute, United States

Role of Myeloid Derived Immune Cells in WM related Immune Suppression

Patricia Mondello, Mayo Clinic-Rochester, United States

Distinct Immune and Genomic Signatures Predict Resistance to Ibrutinib Therapy in Waldenstrom's macroglobulinemia

Tina Bagratuni, University of Athens, Greece

Panel Discussion, All Session IV Speakers

[12:30-1:30 PM] LUNCH

Pasadena Hall

Consensus Panel Breakout Sessions (For Panel Members)

CHINO A&B Conference Rooms

PANEL 1: Defining Uniform Criteria for MRD Assessment in WM

PANEL 2: Response Criteria for Non-IgM LPL Incl. Hyposecretory/Non-secretory LPL

[1:30-2:45 PM] Session: V

Signaling Networks and Novel Targets in WM

Ken Anderson, Noopur Raje [Chairs]

Targeting IRAK signaling in MYD88 Mutated Lymphomas

John Hatcher, Dana Farber Cancer Institute, United States

Targeting HCK in BTK-Inhibitor resistant MYD88 Mutated Lymphomas

Shirong Liu, Dana Farber Cancer Institute, United States

Mechanistic Insights into Abrogating T-Cell exhaustion from A MYD88 Mutated Transgenic Murine Model

Christelle Vincent-Faber, University of Limoges, France

Targeting Alarmins to Improve T-Cell Immunity and Cellular Therapy Outcomes in MM: Lessons for WM

Adolfo Aleman, MT Sinai Medical Center, United States

Can Animal Models help us Identify and Optimize Cellular Therapy Options for WM?

Jose Martinez-Climent, University of Navarra, Spain

Panel Discussion, All Session V Speakers

[2:45-3:15 PM] Afternoon Break & Networking

Ballroom Terrace

[3:15-4:15 PM] Session: VI

Plenary Session I

Oral Presentations- Basic and Translational

Nikhil Munshi, Marzia Varettoni [Chairs]

Familial WM is Associated with Chr14q and Expression of HLA-DRB5

Zachary Hunter, Dana Farber Cancer Institute, United States

Spatially Organized Tumor-Immune Niches Mark Disease Evolution in WM

David M. Cordas dos Santos, Dana Farber Cancer Institute, United States

Cell Differentiation Stage Drives Mechanisms of Apoptosis Evasion in WM

Isacco Ferrarini, University of Verona, Italy

Transcription Factor Networks Critical for WM cells: Functional Characterization and Therapeutic Implications

Torsten Steinbrunn, University of Wurzburg, Germany

Panel Discussion, All Session VI Speakers

[4:15-4:45 PM] Session VII

Keynote Lecture

AI Powered Workflows for Blood Cancers

Keynote Speaker: Jansen Seheult, Mayo Clinic-Rochester, United States

Keynote Moderator: Stephen Ansell, Mayo Clinic-Rochester, United States

[6:00-10:00 PM] Opening Ceremonies and Awards Presentation

Palm Springs Art Museum

[5:30-6:00 PM] Buses depart from the Hotel lobby

- **Keynote Speaker:** TBD, BeOne Medicines, USA Inc.
- **Presentation of Robert A. Kyle Award**
- **Presentation of Jan Gosta Waldenstrom Award**
- **Presentation of the Peter S. Bing Humanitarian Awards**

Thursday, October 15, 2026
California Grand Ballroom

[8:00-9:00 AM] Session VIII

Special Topics in WM

Stathis Kastiris, Jorge Castillo [Chairs]

Management of Transformed WM

Eric Durot, CHU DE REIMS, France

Management of IgM Peripheral Neuropathy

Shayna Sarosiek, Dana Farber Cancer Institute, United States

Management of Bing Neel Syndrome

Naohiro Sekiguchi, National Disaster Medical Center, Japan

Management of WM Related Amyloidosis

Monique Minnema, University of Utrecht, The Netherlands

Panel Discussion, All Session VIII Speakers

[9:00-10:00 AM] Session IX

Novel Approaches for Treatment Naïve WM- Clinical Studies I

Meletios Dimopoulos, Judith Trotman [Chairs]

Prospective Randomized Study of DRC vs. Bortezomib-DRC (ECWM-1 Trial) in Treatment naïve WM

Pierre Morel, CHU Amiens Picardie, France

Prospective Study of Bortezomib, Ibrutinib and Rituximab (ECWM-2 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

Prospective Study of Ibrutinib and Carfilzomib vs. Ibrutinib (CZAR-1) in Treatment naïve WM

Stathis Kastiris, University of Athens, Greece

Randomized Phase II Study of DRC vs. Venetoclax and Rituximab (VIWA-1 Trial) in Treatment naïve WM

Christian Buske, University of Ulm, Germany

Panel Discussion, All Session IX Speakers

[10:00-10:30 AM] Mid-Morning Break & Networking
Ballroom Terrace

[10:30-11:30 AM] Session X

Novel Approaches for Treatment naïve WM-Clinical Studies II

M.J. Kersten, Constantine Tam [Chairs]

Prospective Study of Bendamustine-Rituximab followed by Observation or maintenance Rituximab
Mathias Rummel, University of Giessen, Germany

Prospective Study of Bendamustine, Rituximab and Acalabrutinib in Treatment naïve WM
Neil Berinstein, Sunnybrook Health Sciences Center, Canada

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM-China Study
Lugui Qiu, Chinese Academy of Medical Sciences, China

Prospective Study of Bendamustine, Rituximab and Zanubrutinib in Treatment naïve WM- USA Study
Andrew Branagan, Massachusetts General Hospital, United States

Panel Discussion, All Session X Speakers

[11:30-12:30] Session XI

Novel Approaches for Previously Treated WM

Moshe Gatt, Sheeba Thomas [Chairs]

Prospective Study of Pirtobrutinib monotherapy in previously treated WM
M. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

Prospective Study of Pirtobrutinib and Venetoclax in previously treated WM
Jorge Castillo, Dana Farber Cancer Institute, United States

Phase 1 CaDAnCe-101 Update: Tacabrutideg (BGB-16673) in R/R WM
Anna Maria Frustaci, ASST Grande Ospedale Metropolitano Niguarda, Italy

Prospective Study of the CD19-ADC Loncastuximab in Previously Treated WM
Shayna Sarosiek, Dana Farber Cancer Institute, United States

Panel Discussion, All Session XI Speakers

[12:30-1:30 PM] LUNCH

Pasadena Hall

Consensus Panel Breakout Sessions (For Panel Members)

CHINO A&B Conference Rooms

PANEL 3: Management of Peripheral Neuropathy in WM and IgM related Disorders

PANEL 4: Updated Recommendations for Management of Treatment naïve, symptomatic WM

[12:30-1:30 PM] Young Investigator Mentoring Advisory Meeting

Pueblo Conference Room

[1:30-2:30 PM] Session: XII

Plenary Session II

Oral Presentations- Clinical Studies

Ranjana Advani, Evangelos Terpos [Chairs]

MAGNAZ-Trial: A Multicenter Phase II Study of Zanubrutinib Treatment in Anti-MAG Polyneuropathy

Marieke Bruinsma, UMC Utrecht, The Netherlands

Venetoclax in IgM-Associated AL Amyloidosis: A Multicenter Retrospective Analysis

Saurabh Zanwar, Mayo Clinic-Rochester, United States

Outcomes of CD19 CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia Versus de novo Aggressive Large B-Cell Lymphoma: A DESCAR-T Registry and International Collaborative Study

Eric Durot, CHU de Reims, France

CAR T-Cell Therapy for Transformed WM to High-Grade Lymphoma: An EBMT LWP Registry Analysis Update

Charalampia Kyriakou, University College London Hospitals NHS Foundation Trust, United Kingdom

Panel Discussion, All Session XII Speakers

[2:30-4:00 PM] Session XIII

Plenary Session III

Young Investigator [YIA] Oral Presentations

Andrew Branagan, Josephine Vos [Chairs]

Pronounced Intra-clonal Diversification Underlies a complex Immunogenetic Landscape in WM

Aikaterini Mallou, Center for Research & Technology Hellas, Greece

Pathological and Morphological Characterization of Malignant and Pre-malignant B-Cell Disease in a MYD88 L265P/Chr6q-deletion Mouse Model

Tuyet Nguyen, Dana Farber Cancer Institute, United States

Baseline Demographic or Prognostic Factors do not Predict Achievement of MRD Negativity in Peripheral Blood or Bone marrow after Treatment in the BRAWM Trial

Arjun Pandey, University of Toronto, Canada

Exploring AL Amyloidosis by the Underlying Clone: B-Cell versus Plasma Cell Disorder in a Dutch population-based Registry

Wouter Verhaar, Amsterdam UMC, The Netherlands

Light Chain Amyloidosis in WM/Lymphoplasmacytic Lymphoma: Treatment Strategies and Outcomes in 74 Cases

Nicolò Danesin, University of Padova, Italy

Genomic and Therapeutic Similarities Between Non-IgM Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia: Isotype-Driven Clinical Differences in a Multicenter Cohort

Alberto Guijosa, Dana Farber Cancer Institute, United States

Panel Discussion, All Session XIII Speakers

[4:00-6:00 PM] Session XIV
Poster Session & Reception
Sierra-Ventura Hall

[7:00-9:00 PM] Invited Faculty Dinner Reception- Thompson Palm Springs
[6:30 PM] Departure from the Hotel Lobby

[6:00-10:00 PM] Palm Springs Street Fair Festival, Palm Canyon Drive

Friday, October 16, 2026
California Grand Ballroom

[8:00-9:30 AM] Session XV
Great Debates in WM
Eva Kimby, Irene Ghobrial [Chairs]

[8:00-8:20 AM] Great Debate I
Should Family of Patients with Inherited WM Predisposition be Evaluated for WM and Related Disorders?

YES! They should be evaluated
Sigurdur Kristinson, University of Iceland, Iceland

NO! They should NOT be evaluated
M.J Kersten, University of Amsterdam, The Netherlands

[8:20-8:40 AM] Great Debate II
Should TP53 Mutation Status be considered in Treatment Decisions?

YES! They should be considered
Jorge Castillo, Dana Farber Cancer Institute, United States

NO! They should NOT be considered
Christian Buske, University of Ulm, Germany

[8:40-9:00] Great Debate III
Should Chemo-immunotherapy be used before or after BTK-Inhibitors in WM?

They should be used BEFORE BTK Inhibitors
Meletios Dimopoulos, University of Athens, Greece

They should be used AFTER BTK Inhibitors
Alessandra Tedeschi, Niguarda Hospital, Italy

[9:00-9:20 AM] Great Debate IV

Do we still need stem cell transplantation in the era of targeted and cellular therapies in WM?

NO, we do not need stem cell transplantation

Constantine Tam, Alfred Hospital, Monash University, Australia

YES, we DO need stem cell transplantation

Charalampia Kyriakou, University College London Hospitals NHS Trust, United Kingdom

**[9:30-10:00 AM] Mid-Morning Break & Networking
Ballroom Terrace**

[10:00-11:00 AM] Session XVI

Clinical Trials in Progress for WM- Non-Cellular Therapies

Jeffrey Matous, Roger Owen [Chairs]

Randomized Clinical Trial of Ibrutinib vs. DRC in Treatment naïve WM: RAINBOW Trial

Rebecca Auer, Royal London Hospital, United Kingdom

Prospective Study of Pirtobrutinib, Rituximab, and Venetoclax (PROVEN Study) in Treatment naïve WM

M. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

Phase 2 Study of the BCL2 Inhibitor Sonrotoclax in relapsed refractory WM

Ramon Garcia Sanz, Universitario Gregorio Marañon De Madrid, Spain

Clinical Trial of Sonrotoclax and BGB-16673 in Treatment naïve and BTK-Inhibitor naïve WM: Sounder Trial

Judith Trotman, University of Sydney, Australia

Panel Discussion, All Session XVI Speakers

BLISS FAMILY WORKSHOP FOR ADVANCING CELLULAR THERAPIES IN WM

[11:00-11:30 AM] Session XVII

Keynote Lecture 1

Bringing Cellular Therapies to WM: The Lymphoma Experience

Keynote Speaker: M. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

Keynote Moderator: Ranjana Advani, Stanford University, United States

Keynote Lecture 2

Bringing Cellular Therapies to WM: The Myeloma Experience

Keynote Speaker: Noopur Raje, Mass General Hospital, United States

Keynote Moderator: Prashant Kapoor, Mayo Clinic-Rochester, United States

[11:30-12:30 PM] LUNCH

Pasadena Hall

Consensus Panel Breakout Sessions (For Panel Members)

CHINO Conference Room

PANEL 5: Updated Recommendations for Management of Relapsed-Refractory WM

PANEL 6: Targets and Priorities for Advancing Cellular Therapies in WM

[12:30-1:30 PM] Session XVIII

Clinical Trials in Progress for WM- Cellular Therapies I

Hermann Einsele, Edward Stadtmauer [Chairs]

Clinical Trial of the CD19 TCE AZD0486 in Previously Treated WM

Tarek Mouhieddine, Dana Farber Cancer Institute, United States

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- USA Experience

Gottfried von Keudell, Beth Israel Deaconess Medical Center, United States

Clinical Trial of the CD20 TCE Epcoritamab in previously treated WM- European Experience

Josephine Vos, University of Amsterdam, The Netherlands

Randomized Study of Odronextamab vs. Odronextamab and Zanubrutinib in WM: MOZART TRIAL

Christian Buske, University of Ulm, Germany

Panel Discussion, All Session XVIII Speakers

[1:30-2:30 PM] Session XIX

Clinical Trials in Progress for WM- Cellular Therapies II

Moshe Gatt, Noopur Raje [Chairs]

Clinical Trial of the BCMA TCE Etentamig in Previously Treated WM

Prashant Kapoor, Mayo Clinic-Rochester, United States

Clinical Trial of the BCMA TCE Teclistamab in Previously Treated WM

Andrew Branagan, Mass General Hospital, United States

Clinical Trial of Mosunetuzumab and Pirtobrutinib in previously treated WM

Narendranath Epperla, University of Utah, United States

Prospective Study of Epcoritamab and Zanubrutinib in Treatment naïve, Symptomatic WM

Camille Edwards, Dana Farber Cancer Institute, United States

Panel Discussion, All Session XIX Speakers

[2:30-3:00 PM] Afternoon Break & Networking
Ballroom Terrace

[3:00-4:00 PM] Session XX

Advisory Panel on Advancing Cellular Therapies in WM

Stephen Ansell, Steven Treon [Chairs]

Single versus Dual Antigen Targeting for Cellular Therapies in WM

Edward Stadtmauer, Perelman Schl of Med., University of Pennsylvania, United States

Prioritizing TCE and CAR T cell studies in WM: Which Options, and for Which patients?

Hermann Einsele, University of Wurzburg, Germany

Developing MRD response assessment tools for dynamic risk assessment in WM

Nikhil Munshi, Dana Farber Cancer Institute, United States

What's next in the world of Cellular Therapies that WM can serve as a disease model?

Eric Smith, Dana Farber Cancer Institute, United States

Panel Discussion, All Session XX Speakers

[6:00-10:00 PM] Closing Ceremonies and Young Investigator Awards Presentation
Westin Rancho Mirage

[5:00-5:30 PM] Buses depart from the Hotel

- **Presentation of the Young Investigator Awards**
- **Announcement and Welcome to IWWM-14, 2028**

Saturday, October 17, 2026
Mojave Learning Center

[8:00-9:00 AM] Morning Break & Networking
Ballroom Terrace

[9:00-12:00 PM] Session XXI
Joint IWWM & IWMF WM Patient Symposium

Highlights of IWWM-13 for WM Patients & Caregivers
Ranjana Advani, Prashant Kapoor [Chairs]

[9:00 AM] Introductions

Paul Kitchen, International Waldenstrom's Macroglobulinemia Foundation
Delora Senft, International Waldenstrom's Macroglobulinemia Foundation

[9:15 AM] Progress in Genomics and Personalized Treatment Approaches for WM

Tina Bagratuni, University of Athens, Greece
Zachary Hunter, Dana Farber Cancer Institute, United States

[9:45 AM] New Targets and Drug Development Opportunities

Romanos Sklavenitis-Pistofidis, City of Hope, United States
John Hatcher, Dana Farber Cancer Institute, United States

[10:15 AM] Highlights of Clinical Trials Reported at IWWM-13

Christian Buske, University of Ulm, Germany
Shayna Sarosiek, Dana Farber Cancer Institute, United States

[10:45 AM] The New Frontier: Cellular Therapy Trials in WM

Monique Minnema, University of Utrecht, The Netherlands
M. Lia Palomba, Memorial Sloan Kettering Cancer Center, United States

[11:15 AM] Summary of Great Debates in WM: What is Still Controversial, and What Do the Experts Think?

Josephine Vos, University of Amsterdam, The Netherlands
Andrew Branagan, Massachusetts General Hospital, United States

[11:45 AM] Conclusions

Ranjana Advani, University of Stanford, United States
Prashant Kapoor, Mayo Clinic-Rochester, United States

[12:00-1:00 PM] LUNCH
Pasadena Hall

[9:00-12:00 PM] WM-NET Strategic Initiatives Meeting
CHINO Meeting Room

Jorge Castillo [Chair]

[7:00-10:00 PM] BeOne-IWWM13 Dinner Reception, Melvyn's
[6:30 PM] Buses depart from the Hotel, by invitation